Another positive step towards cure / mitigation of Alzheimer's disease.

AC Immune announced today in a company release that one of the primary objectives of the Phase 2 trial with partner Genentech (Roche Group) has been met.

AC Immune's stock is up 70% as a result.

Announcement from AC Immune:

https://ir.acimmune.com/news-releases/news-release-details/ac-immune-announces-first-positive-cognitive-results-tau
$IMR (+3,13 %)
$RHO (+0,53 %)